ZENTALIS PHARMACEUTICALS - MEDIAN OVERALL SURVIVAL OF 15.8 MONTHS WITH AZENOSERTIB IN CYCLIN E1-POSITIVE PROC

Reuters · 1d ago

Please log in to view news